Who are LevoCept's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bazedoxifene/Conjugated Estrogen, Tamoxifen Oral Tablet, E2Nomac, fenofibrate and tibolone, Metformin + Clomiphene, tamoxifen citrate (Tamoxifen).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levocept.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LevoCept — Competitive Intelligence Brief

LevoCept (LevoCept) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Estrogen Receptor Modulator (SERM). Area: Women's Health / Endocrinology.

phase 3 Selective Estrogen Receptor Modulator (SERM) Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Women's Health / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

LevoCept (LevoCept) — Sebela Women's Health Inc.. LevoCept is a selective estrogen receptor modulator (SERM) that modulates estrogen signaling to treat menopausal symptoms and related conditions in women.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LevoCept TARGET	LevoCept	Sebela Women's Health Inc.	phase 3	Selective Estrogen Receptor Modulator (SERM)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Bazedoxifene/Conjugated Estrogen	Bazedoxifene/Conjugated Estrogen	University of North Carolina, Chapel Hill	marketed	Selective Estrogen Receptor Modulator (SERM) combined with Conjugated Estrogens	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Tamoxifen Oral Tablet	Tamoxifen Oral Tablet	Samsung Medical Center	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor alpha (ERα)
E2Nomac	E2Nomac	Sydney Centre for Reproductive Health Research	marketed	Selective Estrogen Receptor Modulator (SERM)	Estrogen receptor (ER-α/ER-β)
fenofibrate and tibolone	fenofibrate and tibolone	Keogh Institute for Medical Research	marketed	Fibrate + Selective Estrogen Receptor Modulator (SERM)	PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)
Metformin + Clomiphene	Metformin + Clomiphene	University of Auckland, New Zealand	marketed	Combination therapy: biguanide + selective estrogen receptor modulator (SERM)	Metformin: AMP-activated protein kinase (AMPK); Clomiphene: estrogen receptor (ER)
tamoxifen citrate (Tamoxifen)	tamoxifen citrate (Tamoxifen)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor alpha (ERα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Estrogen Receptor Modulator (SERM) class)

Eli Lilly and Company · 1 drug in this class
Sebela Women's Health Inc. · 1 drug in this class
Sydney Centre for Reproductive Health Research · 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LevoCept — Competitive Intelligence Brief. https://druglandscape.com/ci/levocept. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab